Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Fexinidazole Formulations in Healthy Volunteers
NCT02571062Phase 1Completed
- Sponsor
- Drugs for Neglected Diseases initiative
- Start
- Mar 2015
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Fexinidazole in African trypanosomiasis (HAT) (2 arms), sponsored by Drugs for Neglected Diseases initiative. Primary endpoint: Pharmacokinetic parameters of fexinidazole at 168 hours. Started Mar 2015; status: completed.
02
Drugs
Fexinidazole
03
Conditions
African trypanosomiasis (HAT)
Beyond the preview
Go deeper on NCT02571062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02571062.